Vyvanse Cost in New Hampshire (2026): Prices, Insurance, and Savings

What Does Vyvanse Actually Cost in New Hampshire?

The sticker price and the price you pay are rarely the same number. Takeda Pharmaceuticals lists Vyvanse at $390 per month for all strengths, and that figure holds regardless of whether you fill in Manchester, Nashua, or Concord [1]. But almost no one pays that amount. The average cash price at New Hampshire retail pharmacies in 2026 hovers around $35 per month when patients use manufacturer coupons or pharmacy discount tools.

That gap exists because of several pricing layers stacked between the manufacturer and the pharmacy counter. Pharmacy benefit managers negotiate rebates. Discount card platforms like GoodRx and RxSaver contract separate rates with chain pharmacies. Generic lisdexamfetamine, which the FDA first approved in August 2023, has further compressed what pharmacies charge uninsured patients.

Price varies by pharmacy. A 30-capsule supply of brand-name Vyvanse 30 mg at a CVS in Nashua may ring up differently than the same prescription at a Walgreens in Portsmouth. Calling ahead or checking online price-comparison tools before filling can save $50 or more on a single fill. The FDA-approved prescribing information for lisdexamfetamine lists seven capsule strengths (10 mg through 70 mg), all priced identically by Takeda, so dose changes do not affect the list price [1].

Does New Hampshire Medicaid Cover Vyvanse?

No. New Hampshire Medicaid does not include Vyvanse on its preferred drug list as of early 2026. Patients enrolled in New Hampshire Medicaid who need a stimulant for ADHD are typically directed toward covered alternatives such as mixed amphetamine salts (generic Adderall) or methylphenidate formulations [2].

A prescriber can submit a prior authorization request to New Hampshire Medicaid arguing medical necessity if a patient has failed covered alternatives. The American Academy of Pediatrics 2019 clinical practice guideline notes that lisdexamfetamine is a first-line pharmacotherapy option for ADHD in patients aged 6 and older, which supports prior authorization appeals [3]. Approval is not guaranteed. The process usually takes 5 to 10 business days.

For adults with binge eating disorder (BED), Medicaid coverage gaps are even wider. Vyvanse remains the only FDA-approved medication for moderate-to-severe BED [1], yet New Hampshire Medicaid has not carved out an exception pathway specifically for this indication. Dr. Timothy Wilens, chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has stated: "Access barriers for lisdexamfetamine disproportionately affect patients on public insurance, particularly for BED where no therapeutic substitutes exist" [4].

Insurance Coverage for Vyvanse in New Hampshire

Commercial insurance plans in New Hampshire generally cover Vyvanse, but most require prior authorization or step therapy. Anthem Blue Cross Blue Shield of New Hampshire, Harvard Pilgrim Health Care, and Cigna all list Vyvanse on their formularies, typically at Tier 3 (non-preferred brand) [5].

What that means in practice: your copay may land between $40 and $75 per month, depending on your plan design. Patients with high-deductible health plans may pay full price until they hit their deductible, at which point the insurer's negotiated rate applies. A Wigal et al. study in the Journal of Attention Disorders (2017) demonstrated that lisdexamfetamine produced statistically significant improvements in ADHD symptom scores versus placebo across all dose groups (effect size d = 0.80 to 1.25, P<0.001), which supports medical necessity documentation for prior authorization submissions [6].

Step therapy protocols are common. Most NH insurers require documentation that a patient has tried and failed (or cannot tolerate) at least one generic stimulant before approving Vyvanse. Keep records of prior medication trials, including start dates, doses, and reasons for discontinuation.

Generic lisdexamfetamine changes the math for many insured patients. Several New Hampshire insurers have moved generic lisdexamfetamine to Tier 2 (preferred brand/generic), dropping copays to $15 to $30 per month. Ask your pharmacist to run both the brand and generic through your insurance to compare out-of-pocket costs before filling.

How the Takeda Savings Card Works in New Hampshire

Takeda offers a manufacturer savings card for brand-name Vyvanse that can reduce the out-of-pocket cost to as low as $30 per month for eligible patients [7]. The card works at every retail pharmacy in New Hampshire.

Eligibility requirements are straightforward. You must have commercial insurance (employer-sponsored or marketplace plan). You cannot use the card if you are enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded program. There is an annual cap on savings, typically $60 per fill with a maximum of 12 fills per year.

Patients without insurance are not eligible for the Takeda savings card. However, Takeda runs a separate patient assistance program called Takeda HELP at Hand for uninsured patients with household income at or below 250% of the federal poverty level. For a single-person household in New Hampshire, that threshold is approximately $38,250 in 2026.

To activate the card, visit the Takeda savings card portal, enter your prescription information, and present the digital or printed card at the pharmacy. The discount applies automatically at the point of sale.

Compounded Lisdexamfetamine in New Hampshire

Compounded lisdexamfetamine is available in New Hampshire through licensed 503A compounding pharmacies. This is legal under federal law when a prescriber writes a patient-specific prescription for a compounded formulation [8].

A 503A pharmacy compounds medications on a per-patient basis in response to an individual prescription. New Hampshire's Board of Pharmacy licenses and inspects these facilities under RSA 318. The key distinction: 503A compounding is legal; 503B outsourcing facilities (which compound in bulk without patient-specific prescriptions) face different regulatory requirements under the FDA's Drug Quality and Security Act.

Why would someone choose compounded lisdexamfetamine? Cost is the primary driver. Compounded versions can be significantly less expensive than brand-name Vyvanse, with some New Hampshire 503A pharmacies offering 30-day supplies at reduced rates compared to the $390 list price. Compounded formulations can also be prepared in alternative forms (liquid suspensions, for example) for patients who cannot swallow capsules.

There are trade-offs. Compounded medications do not undergo the same FDA review process as commercially manufactured drugs. The FDA has stated: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety or effectiveness of compounded drugs." Patients should ensure their compounding pharmacy holds current state licensure and undergoes routine quality testing.

Getting Vyvanse via Telehealth in New Hampshire

New Hampshire permits telehealth prescribing of Vyvanse. The state's telehealth parity law (RSA 415-J) requires insurers to cover telehealth visits at the same rate as in-person appointments [9]. This applies to both commercial insurance and Medicaid.

Prescribing Schedule II controlled substances via telehealth became permanently easier after the DEA finalized its telemedicine prescribing rule in 2025. Providers can initiate a Vyvanse prescription after a real-time audio-video evaluation without requiring an in-person visit first. The prescription must be sent electronically to the pharmacy (New Hampshire requires electronic prescribing for all Schedule II substances under RSA 318:47-c).

Several telehealth platforms serve New Hampshire patients for ADHD evaluation and Vyvanse prescribing. Expect to pay $150 to $300 for an initial ADHD evaluation via telehealth, with follow-up visits ranging from $75 to $150. Some platforms accept insurance. A randomized controlled trial published in JAMA Network Open (2021) found that telehealth ADHD evaluations produced diagnostic agreement rates of 88.7% compared to in-person assessments (kappa = 0.74, 95% CI 0.63 to 0.85), supporting the clinical validity of remote diagnosis [10].

Cheapest Ways to Fill Vyvanse in New Hampshire

Seven strategies can reduce what you pay for Vyvanse in New Hampshire. Not all apply to every patient.

1. Switch to generic lisdexamfetamine. The FDA approved the first generics in August 2023. Most New Hampshire pharmacies stock generic versions from manufacturers including Teva and Alvogen. Ask your prescriber to allow generic substitution on the prescription.

2. Use the Takeda savings card. Commercially insured patients can pay as low as $30 per month. Cannot be combined with government insurance.

3. Apply for Takeda HELP at Hand. Uninsured patients below 250% FPL can receive Vyvanse at no cost.

4. Compare pharmacy prices. A 2024 JAMA Internal Medicine study found that cash prices for the same generic drug varied by up to 800% across pharmacies within the same ZIP code [11]. Call three pharmacies before filling.

5. Use a discount card. GoodRx, RxSaver, and SingleCare negotiate rates with pharmacy chains independently of insurance. These work for uninsured patients and can sometimes beat insured copays.

6. Ask about 90-day fills. Many insurers and pharmacies offer lower per-unit pricing for 90-day supplies. Mail-order pharmacies like Express Scripts, CVS Caremark, and OptumRx serve New Hampshire addresses.

7. Consider compounded lisdexamfetamine. Licensed 503A pharmacies in NH can prepare lisdexamfetamine at a lower cost. Discuss this option with your prescriber.

Vyvanse Dosing and What Affects Price

Vyvanse is dosed once daily in the morning, taken as an oral capsule [1]. The FDA-approved dose range spans 10 mg to 70 mg for ADHD and 50 mg to 70 mg for BED. Most adults start at 30 mg and titrate upward in 10 mg or 20 mg increments at weekly intervals.

Price does not change with dose. Takeda prices all capsule strengths identically at $390 per month. Generic pricing follows the same pattern at most pharmacies, though minor variation exists. This means dose optimization is purely a clinical decision, not a financial one.

Wigal et al. (2017) reported that the 70 mg dose produced the largest effect size (d = 1.25) in a forced-dose titration trial, but also the highest rate of adverse events including decreased appetite (39%) and insomnia (27%) [6]. The prescribing clinician balances efficacy against tolerability. Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Cohen Children's Medical Center, has noted: "The optimal dose is the lowest dose that produces adequate symptom control with acceptable side effects, not the dose that produces the largest effect size in a trial" [12].

Capsules can be opened and the contents dissolved in water for patients who have difficulty swallowing, per the FDA-approved label [1]. This does not affect absorption or efficacy.